Chiasma To Report Fourth Quarter and Full Year 2019 Financial Results On March 16, 2020
March 09 2020 - 4:05PM
Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical
company focused on improving the lives of patients with rare and
serious chronic diseases, today announced that it will host a
conference call and live audio webcast on Monday, March 16,
2020 at 5:00 p.m. Eastern Time to discuss financial
results for the quarter and year ended December 31, 2019 and
to provide a business update.
Conference Call Details
Monday, March 16th @ 5pm Eastern
Time
Domestic: |
1-877-407-4018 |
International: |
1-201-689-8471 |
Conference ID: |
13699225 |
Webcast: |
https://edge.media-server.com/mmc/p/b4e8rvsn |
|
|
A live audio webcast of the call may also be accessed under
"Events & Presentations" on the News &
Investors section of the Company's
website, http://ir.chiasmapharma.com/events-presentations. An
archived replay of webcast will be available on the Company’s
website approximately two hours after the event. The archived
webcast will be available for one year.
About Chiasma
Chiasma is focused on improving the lives of
patients who face challenges associated with their existing
treatments for rare and serious chronic diseases. Employing its
Transient Permeability Enhancer (TPE®) technology platform, Chiasma
seeks to develop oral medications that are currently available only
as injections. In July 2019, the company reported positive topline
data from its CHIASMA OPTIMAL Phase 3 clinical trial for its
octreotide capsules product candidate, conditionally trade named
MYCAPSSA, for the maintenance therapy of adult patients with
acromegaly in whom prior treatment with somatostatin analogs has
been shown to be effective and tolerated. Prior to trial
initiation, the company reached agreement with the FDA on the
design of the trial through a special protocol assessment. In
January 2020, the FDA accepted the company’s NDA resubmission
seeking marketing approval of MYCAPSSA in the U.S. The PDUFA target
action date is June 26, 2020. Chiasma is headquartered in
Needham, MA with a wholly-owned subsidiary in Israel. MYCAPSSA, TPE
and CHIASMA are registered trademarks of Chiasma. For more
information, please visit the company’s website at
www.chiasma.com.
Corporate Contact:Dawn SchottlandtVice
President, Investor Relations and Corporate
Communications617-928-5208dawn.schottlandt@chiasmapharma.com
Chiasma (NASDAQ:CHMA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Chiasma (NASDAQ:CHMA)
Historical Stock Chart
From Apr 2023 to Apr 2024